
Yersinia pestis: Evolution, Diagnosis and Treatment
Evolution
Yersinia pestis diverged from Y. pseudotuberculosis which has the main transmission route of faecal-oral around 1,500-20,000 years ago and the acquisition of ymt gene allowed for the survival of the bacteria in fleas giving Y. pestis ectoparasite transmissibility ( Zhou & Yang, 2009). Additionally, the pPCP1 gene which encodes the Pla enzyme in Yersinia pestis can increase the bacteria's virulence, using the enzyme's coagulase activity (active at ≤28 °C) to form a fibrin clot to obstruct the fleas digestive tract and the fibrinolytic activity (active at ≥37 °C ) to prevent blood clotting in humans at the insect's bite point, thus allowing the bacteria to bypass the skin and reach the draining lymph nodes. However, there are strains of Y. pestis which lack Pla and still retain full virulence, indicating that whilst Pla may be an affective target for vaccines against some strains of Y. pestis that the diversity of Y. pestis strains would require different targets for vaccination ( Sebbane et al., 2020).
Yersinia pestis uses a type 3 secretion system (T3SS) to translocate Yersinia outer membrane proteins (Yops) into host cells which then enables Y. pestis to evade the immune system through mechanisms such as downregulating the production of pro-inflammatory cytokines, inhibiting phagocytosis and inducing cell death of host cells. This T3SS-mediated neutralization of immune cells allows the bacterium to replicate undetected and spread silently in what is known as the "pre-inflammatory phase" before the systemic dissemination and detection of Yersinia pestis with the appearance of clinical symptoms in the "pro-inflammatory phase" (Demeure et al., 2019).

Diagnosis and Treatment
The change from an absence of an immune response to the sudden onset of the pro-inflammatory phase and the initial non-specific display of symptoms such as fever and headache can lead to delays in diagnosis and treatment. Diagnostics for the plague can be done through isolating Yersinia pestis from tissues or body fluids or the less preferred method of serological testing for F1 antigen antibodies (Glatter & Finkelman, 2021). The standard treatment of plague is Streptomycin, tetracyclines and sulphonamides. Gentamicin and fluoroquinolones (Stenseth et al., 2008).
People with Familia Mediterranean Fever (FMF) whose symptoms include abdominal pain, arthritis and fevers, have gene mutations which have been linked to plague immunity. Pyrin which maintains pathogen defence, promotes fever production through IL-1β and facilitates programmed cell death is "always on" in those with FMF and Y. pestis turns off the Pyrin gene in those without the mutation blocking the immune system from having a strong response to the pathogen (Glatter & Finkelman, 2021).
References
Demeure, C. E., Dussurget, O., Mas Fiol, G., Le Guern, A. S., Savin, C., & Pizarro-Cerdá, J. (2019). Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. Genes and immunity, 20(5), 357–370. https://doi.org/10.1038/s41435-019-0065-0
Glatter, K. A., & Finkelman, P. (2021). History of the Plague: An Ancient Pandemic for the Age of COVID-19. The American journal of medicine, 134(2), 176–181. https://doi.org/10.1016/j.amjmed.2020.08.019
Sebbane, F., Uversky, V. N., & Anisimov, A. P. (2020). Yersinia pestis Plasminogen Activator. Biomolecules, 10(11), 1554. https://doi.org/10.3390/biom10111554
Stenseth, N. C., Atshabar, B. B., Begon, M., Belmain, S. R., Bertherat, E., Carniel, E., Gage, K. L., Leirs, H., & Rahalison, L. (2008). Plague: past, present, and future. PLoS medicine, 5(1), e3. https://doi.org/10.1371/journal.pmed.0050003
Zhou, D., & Yang, R. (2009). Molecular Darwinian evolution of virulence in Yersinia pestis. Infection and immunity, 77(6), 2242–2250. https://doi.org/10.1128/IAI.01477-08
How BioLabTests can support you
If you would like to explore our microbiology testing portfolio, please do not hesitate to get in touch with a member of our team on +44 (0) 333 240 8308 or simply complete our contact form.
Please note that BioLabTests does not test human, animal or food samples and we do not test for viruses.



